1 Market Overview

1.1 Product Overview and Scope of CAR T-Cell Immunotherapy

1.2 Classification of CAR T-Cell Immunotherapy by Type

1.2.1 Overview: Global CAR T-Cell Immunotherapy Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global CAR T-Cell Immunotherapy Revenue Market Share by Type in 2021

1.2.3 Monotherapy

1.2.4 Combination Therapy

1.3 Global CAR T-Cell Immunotherapy Market by Application

1.3.1 Overview: Global CAR T-Cell Immunotherapy Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hematologic Malignancies

1.3.3 Solid Malignancies

1.4 Global CAR T-Cell Immunotherapy Market Size & Forecast

1.5 Global CAR T-Cell Immunotherapy Market Size and Forecast by Region

1.5.1 Global CAR T-Cell Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global CAR T-Cell Immunotherapy Market Size by Region, (2017-2022)

1.5.3 North America CAR T-Cell Immunotherapy Market Size and Prospect (2017-2028)

1.5.4 Europe CAR T-Cell Immunotherapy Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific CAR T-Cell Immunotherapy Market Size and Prospect (2017-2028)

1.5.6 South America CAR T-Cell Immunotherapy Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa CAR T-Cell Immunotherapy Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 CAR T-Cell Immunotherapy Market Drivers

1.6.2 CAR T-Cell Immunotherapy Market Restraints

1.6.3 CAR T-Cell Immunotherapy Trends Analysis

2 Company Profiles

2.1 AbbVie

2.1.1 AbbVie Details

2.1.2 AbbVie Major Business

2.1.3 AbbVie CAR T-Cell Immunotherapy Product and Solutions

2.1.4 AbbVie CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 AbbVie Recent Developments and Future Plans

2.2 Celgene

2.2.1 Celgene Details

2.2.2 Celgene Major Business

2.2.3 Celgene CAR T-Cell Immunotherapy Product and Solutions

2.2.4 Celgene CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Celgene Recent Developments and Future Plans

2.3 Kite Pharma

2.3.1 Kite Pharma Details

2.3.2 Kite Pharma Major Business

2.3.3 Kite Pharma CAR T-Cell Immunotherapy Product and Solutions

2.3.4 Kite Pharma CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Kite Pharma Recent Developments and Future Plans

2.4 Oxford BioMedica

2.4.1 Oxford BioMedica Details

2.4.2 Oxford BioMedica Major Business

2.4.3 Oxford BioMedica CAR T-Cell Immunotherapy Product and Solutions

2.4.4 Oxford BioMedica CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Oxford BioMedica Recent Developments and Future Plans

2.5 Novartis

2.5.1 Novartis Details

2.5.2 Novartis Major Business

2.5.3 Novartis CAR T-Cell Immunotherapy Product and Solutions

2.5.4 Novartis CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Novartis Recent Developments and Future Plans

2.6 Gilead

2.6.1 Gilead Details

2.6.2 Gilead Major Business

2.6.3 Gilead CAR T-Cell Immunotherapy Product and Solutions

2.6.4 Gilead CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Gilead Recent Developments and Future Plans

2.7 Pfizer

2.7.1 Pfizer Details

2.7.2 Pfizer Major Business

2.7.3 Pfizer CAR T-Cell Immunotherapy Product and Solutions

2.7.4 Pfizer CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Pfizer Recent Developments and Future Plans

2.8 Cellectis

2.8.1 Cellectis Details

2.8.2 Cellectis Major Business

2.8.3 Cellectis CAR T-Cell Immunotherapy Product and Solutions

2.8.4 Cellectis CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Cellectis Recent Developments and Future Plans

2.9 Bellicum

2.9.1 Bellicum Details

2.9.2 Bellicum Major Business

2.9.3 Bellicum CAR T-Cell Immunotherapy Product and Solutions

2.9.4 Bellicum CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Bellicum Recent Developments and Future Plans

2.10 Mustang Bio

2.10.1 Mustang Bio Details

2.10.2 Mustang Bio Major Business

2.10.3 Mustang Bio CAR T-Cell Immunotherapy Product and Solutions

2.10.4 Mustang Bio CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Mustang Bio Recent Developments and Future Plans

2.11 CARsgen Therapeutics

2.11.1 CARsgen Therapeutics Details

2.11.2 CARsgen Therapeutics Major Business

2.11.3 CARsgen Therapeutics CAR T-Cell Immunotherapy Product and Solutions

2.11.4 CARsgen Therapeutics CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 CARsgen Therapeutics Recent Developments and Future Plans

2.12 Xyphos

2.12.1 Xyphos Details

2.12.2 Xyphos Major Business

2.12.3 Xyphos CAR T-Cell Immunotherapy Product and Solutions

2.12.4 Xyphos CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Xyphos Recent Developments and Future Plans

2.13 Minerva Biotechnologies

2.13.1 Minerva Biotechnologies Details

2.13.2 Minerva Biotechnologies Major Business

2.13.3 Minerva Biotechnologies CAR T-Cell Immunotherapy Product and Solutions

2.13.4 Minerva Biotechnologies CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Minerva Biotechnologies Recent Developments and Future Plans

2.14 Adaptimmune

2.14.1 Adaptimmune Details

2.14.2 Adaptimmune Major Business

2.14.3 Adaptimmune CAR T-Cell Immunotherapy Product and Solutions

2.14.4 Adaptimmune CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Adaptimmune Recent Developments and Future Plans

2.15 Ziopharm Oncology

2.15.1 Ziopharm Oncology Details

2.15.2 Ziopharm Oncology Major Business

2.15.3 Ziopharm Oncology CAR T-Cell Immunotherapy Product and Solutions

2.15.4 Ziopharm Oncology CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Ziopharm Oncology Recent Developments and Future Plans

2.16 Aurora Biopharma

2.16.1 Aurora Biopharma Details

2.16.2 Aurora Biopharma Major Business

2.16.3 Aurora Biopharma CAR T-Cell Immunotherapy Product and Solutions

2.16.4 Aurora Biopharma CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Aurora Biopharma Recent Developments and Future Plans

2.17 Creative Biolabs

2.17.1 Creative Biolabs Details

2.17.2 Creative Biolabs Major Business

2.17.3 Creative Biolabs CAR T-Cell Immunotherapy Product and Solutions

2.17.4 Creative Biolabs CAR T-Cell Immunotherapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Creative Biolabs Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global CAR T-Cell Immunotherapy Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 CAR T-Cell Immunotherapy Players Market Share in 2021

3.2.2 Top 10 CAR T-Cell Immunotherapy Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 CAR T-Cell Immunotherapy Players Head Office, Products and Services Provided

3.4 CAR T-Cell Immunotherapy Mergers & Acquisitions

3.5 CAR T-Cell Immunotherapy New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global CAR T-Cell Immunotherapy Revenue and Market Share by Type (2017-2022)

4.2 Global CAR T-Cell Immunotherapy Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global CAR T-Cell Immunotherapy Revenue Market Share by Application (2017-2022)

5.2 Global CAR T-Cell Immunotherapy Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America CAR T-Cell Immunotherapy Revenue by Type (2017-2028)

6.2 North America CAR T-Cell Immunotherapy Revenue by Application (2017-2028)

6.3 North America CAR T-Cell Immunotherapy Market Size by Country

6.3.1 North America CAR T-Cell Immunotherapy Revenue by Country (2017-2028)

6.3.2 United States CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

6.3.3 Canada CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

6.3.4 Mexico CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe CAR T-Cell Immunotherapy Revenue by Type (2017-2028)

7.2 Europe CAR T-Cell Immunotherapy Revenue by Application (2017-2028)

7.3 Europe CAR T-Cell Immunotherapy Market Size by Country

7.3.1 Europe CAR T-Cell Immunotherapy Revenue by Country (2017-2028)

7.3.2 Germany CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

7.3.3 France CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

7.3.4 United Kingdom CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

7.3.5 Russia CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

7.3.6 Italy CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific CAR T-Cell Immunotherapy Revenue by Type (2017-2028)

8.2 Asia-Pacific CAR T-Cell Immunotherapy Revenue by Application (2017-2028)

8.3 Asia-Pacific CAR T-Cell Immunotherapy Market Size by Region

8.3.1 Asia-Pacific CAR T-Cell Immunotherapy Revenue by Region (2017-2028)

8.3.2 China CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

8.3.3 Japan CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

8.3.4 South Korea CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

8.3.5 India CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

8.3.7 Australia CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America CAR T-Cell Immunotherapy Revenue by Type (2017-2028)

9.2 South America CAR T-Cell Immunotherapy Revenue by Application (2017-2028)

9.3 South America CAR T-Cell Immunotherapy Market Size by Country

9.3.1 South America CAR T-Cell Immunotherapy Revenue by Country (2017-2028)

9.3.2 Brazil CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

9.3.3 Argentina CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa CAR T-Cell Immunotherapy Revenue by Type (2017-2028)

10.2 Middle East & Africa CAR T-Cell Immunotherapy Revenue by Application (2017-2028)

10.3 Middle East & Africa CAR T-Cell Immunotherapy Market Size by Country

10.3.1 Middle East & Africa CAR T-Cell Immunotherapy Revenue by Country (2017-2028)

10.3.2 Turkey CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

10.3.4 UAE CAR T-Cell Immunotherapy Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global CAR T-Cell Immunotherapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global CAR T-Cell Immunotherapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market CAR T-Cell Immunotherapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global CAR T-Cell Immunotherapy Revenue (USD Million) by Region (2017-2022)

Table 5. Global CAR T-Cell Immunotherapy Revenue Market Share by Region (2023-2028)

Table 6. AbbVie Corporate Information, Head Office, and Major Competitors

Table 7. AbbVie Major Business

Table 8. AbbVie CAR T-Cell Immunotherapy Product and Solutions

Table 9. AbbVie CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Celgene Corporate Information, Head Office, and Major Competitors

Table 11. Celgene Major Business

Table 12. Celgene CAR T-Cell Immunotherapy Product and Solutions

Table 13. Celgene CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Kite Pharma Corporate Information, Head Office, and Major Competitors

Table 15. Kite Pharma Major Business

Table 16. Kite Pharma CAR T-Cell Immunotherapy Product and Solutions

Table 17. Kite Pharma CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Oxford BioMedica Corporate Information, Head Office, and Major Competitors

Table 19. Oxford BioMedica Major Business

Table 20. Oxford BioMedica CAR T-Cell Immunotherapy Product and Solutions

Table 21. Oxford BioMedica CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Novartis Corporate Information, Head Office, and Major Competitors

Table 23. Novartis Major Business

Table 24. Novartis CAR T-Cell Immunotherapy Product and Solutions

Table 25. Novartis CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Gilead Corporate Information, Head Office, and Major Competitors

Table 27. Gilead Major Business

Table 28. Gilead CAR T-Cell Immunotherapy Product and Solutions

Table 29. Gilead CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Pfizer Corporate Information, Head Office, and Major Competitors

Table 31. Pfizer Major Business

Table 32. Pfizer CAR T-Cell Immunotherapy Product and Solutions

Table 33. Pfizer CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Cellectis Corporate Information, Head Office, and Major Competitors

Table 35. Cellectis Major Business

Table 36. Cellectis CAR T-Cell Immunotherapy Product and Solutions

Table 37. Cellectis CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Bellicum Corporate Information, Head Office, and Major Competitors

Table 39. Bellicum Major Business

Table 40. Bellicum CAR T-Cell Immunotherapy Product and Solutions

Table 41. Bellicum CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Mustang Bio Corporate Information, Head Office, and Major Competitors

Table 43. Mustang Bio Major Business

Table 44. Mustang Bio CAR T-Cell Immunotherapy Product and Solutions

Table 45. Mustang Bio CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. CARsgen Therapeutics Corporate Information, Head Office, and Major Competitors

Table 47. CARsgen Therapeutics Major Business

Table 48. CARsgen Therapeutics CAR T-Cell Immunotherapy Product and Solutions

Table 49. CARsgen Therapeutics CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Xyphos Corporate Information, Head Office, and Major Competitors

Table 51. Xyphos Major Business

Table 52. Xyphos CAR T-Cell Immunotherapy Product and Solutions

Table 53. Xyphos CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Minerva Biotechnologies Corporate Information, Head Office, and Major Competitors

Table 55. Minerva Biotechnologies Major Business

Table 56. Minerva Biotechnologies CAR T-Cell Immunotherapy Product and Solutions

Table 57. Minerva Biotechnologies CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Adaptimmune Corporate Information, Head Office, and Major Competitors

Table 59. Adaptimmune Major Business

Table 60. Adaptimmune CAR T-Cell Immunotherapy Product and Solutions

Table 61. Adaptimmune CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Ziopharm Oncology Corporate Information, Head Office, and Major Competitors

Table 63. Ziopharm Oncology Major Business

Table 64. Ziopharm Oncology CAR T-Cell Immunotherapy Product and Solutions

Table 65. Ziopharm Oncology CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Aurora Biopharma Corporate Information, Head Office, and Major Competitors

Table 67. Aurora Biopharma Major Business

Table 68. Aurora Biopharma CAR T-Cell Immunotherapy Product and Solutions

Table 69. Aurora Biopharma CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Creative Biolabs Corporate Information, Head Office, and Major Competitors

Table 71. Creative Biolabs Major Business

Table 72. Creative Biolabs CAR T-Cell Immunotherapy Product and Solutions

Table 73. Creative Biolabs CAR T-Cell Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Global CAR T-Cell Immunotherapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 75. Global CAR T-Cell Immunotherapy Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 76. Breakdown of CAR T-Cell Immunotherapy by Company Type (Tier 1, Tier 2 and Tier 3)

Table 77. CAR T-Cell Immunotherapy Players Head Office, Products and Services Provided

Table 78. CAR T-Cell Immunotherapy Mergers & Acquisitions in the Past Five Years

Table 79. CAR T-Cell Immunotherapy New Entrants and Expansion Plans

Table 80. Global CAR T-Cell Immunotherapy Revenue (USD Million) by Type (2017-2022)

Table 81. Global CAR T-Cell Immunotherapy Revenue Share by Type (2017-2022)

Table 82. Global CAR T-Cell Immunotherapy Revenue Forecast by Type (2023-2028)

Table 83. Global CAR T-Cell Immunotherapy Revenue by Application (2017-2022)

Table 84. Global CAR T-Cell Immunotherapy Revenue Forecast by Application (2023-2028)

Table 85. North America CAR T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 86. North America CAR T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 87. North America CAR T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 88. North America CAR T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 89. North America CAR T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 90. North America CAR T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 91. Europe CAR T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 92. Europe CAR T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 93. Europe CAR T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 94. Europe CAR T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 95. Europe CAR T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 96. Europe CAR T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 97. Asia-Pacific CAR T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 98. Asia-Pacific CAR T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 99. Asia-Pacific CAR T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 100. Asia-Pacific CAR T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 101. Asia-Pacific CAR T-Cell Immunotherapy Revenue by Region (2017-2022) & (USD Million)

Table 102. Asia-Pacific CAR T-Cell Immunotherapy Revenue by Region (2023-2028) & (USD Million)

Table 103. South America CAR T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 104. South America CAR T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 105. South America CAR T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 106. South America CAR T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 107. South America CAR T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 108. South America CAR T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)

Table 109. Middle East & Africa CAR T-Cell Immunotherapy Revenue by Type (2017-2022) & (USD Million)

Table 110. Middle East & Africa CAR T-Cell Immunotherapy Revenue by Type (2023-2028) & (USD Million)

Table 111. Middle East & Africa CAR T-Cell Immunotherapy Revenue by Application (2017-2022) & (USD Million)

Table 112. Middle East & Africa CAR T-Cell Immunotherapy Revenue by Application (2023-2028) & (USD Million)

Table 113. Middle East & Africa CAR T-Cell Immunotherapy Revenue by Country (2017-2022) & (USD Million)

Table 114. Middle East & Africa CAR T-Cell Immunotherapy Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. CAR T-Cell Immunotherapy Picture

Figure 2. Global CAR T-Cell Immunotherapy Revenue Market Share by Type in 2021

Figure 3. Monotherapy

Figure 4. Combination Therapy

Figure 5. CAR T-Cell Immunotherapy Revenue Market Share by Application in 2021

Figure 6. Hematologic Malignancies Picture

Figure 7. Solid Malignancies Picture

Figure 8. Global CAR T-Cell Immunotherapy Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 9. Global CAR T-Cell Immunotherapy Revenue and Forecast (2017-2028) & (USD Million)

Figure 10. Global CAR T-Cell Immunotherapy Revenue Market Share by Region (2017-2028)

Figure 11. Global CAR T-Cell Immunotherapy Revenue Market Share by Region in 2021

Figure 12. North America CAR T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 13. Europe CAR T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Asia-Pacific CAR T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. South America CAR T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Middle East and Africa CAR T-Cell Immunotherapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. CAR T-Cell Immunotherapy Market Drivers

Figure 18. CAR T-Cell Immunotherapy Market Restraints

Figure 19. CAR T-Cell Immunotherapy Market Trends

Figure 20. AbbVie Recent Developments and Future Plans

Figure 21. Celgene Recent Developments and Future Plans

Figure 22. Kite Pharma Recent Developments and Future Plans

Figure 23. Oxford BioMedica Recent Developments and Future Plans

Figure 24. Novartis Recent Developments and Future Plans

Figure 25. Gilead Recent Developments and Future Plans

Figure 26. Pfizer Recent Developments and Future Plans

Figure 27. Cellectis Recent Developments and Future Plans

Figure 28. Bellicum Recent Developments and Future Plans

Figure 29. Mustang Bio Recent Developments and Future Plans

Figure 30. CARsgen Therapeutics Recent Developments and Future Plans

Figure 31. Xyphos Recent Developments and Future Plans

Figure 32. Minerva Biotechnologies Recent Developments and Future Plans

Figure 33. Adaptimmune Recent Developments and Future Plans

Figure 34. Ziopharm Oncology Recent Developments and Future Plans

Figure 35. Aurora Biopharma Recent Developments and Future Plans

Figure 36. Creative Biolabs Recent Developments and Future Plans

Figure 37. Global CAR T-Cell Immunotherapy Revenue Share by Players in 2021

Figure 38. CAR T-Cell Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 39. Global Top 3 Players CAR T-Cell Immunotherapy Revenue Market Share in 2021

Figure 40. Global Top 10 Players CAR T-Cell Immunotherapy Revenue Market Share in 2021

Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 42. Global CAR T-Cell Immunotherapy Revenue Share by Type in 2021

Figure 43. Global CAR T-Cell Immunotherapy Market Share Forecast by Type (2023-2028)

Figure 44. Global CAR T-Cell Immunotherapy Revenue Share by Application in 2021

Figure 45. Global CAR T-Cell Immunotherapy Market Share Forecast by Application (2023-2028)

Figure 46. North America CAR T-Cell Immunotherapy Sales Market Share by Type (2017-2028)

Figure 47. North America CAR T-Cell Immunotherapy Sales Market Share by Application (2017-2028)

Figure 48. North America CAR T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 49. United States CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Canada CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Mexico CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Europe CAR T-Cell Immunotherapy Sales Market Share by Type (2017-2028)

Figure 53. Europe CAR T-Cell Immunotherapy Sales Market Share by Application (2017-2028)

Figure 54. Europe CAR T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 55. Germany CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. France CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. United Kingdom CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Russia CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Italy CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Asia-Pacific CAR T-Cell Immunotherapy Sales Market Share by Type (2017-2028)

Figure 61. Asia-Pacific CAR T-Cell Immunotherapy Sales Market Share by Application (2017-2028)

Figure 62. Asia-Pacific CAR T-Cell Immunotherapy Revenue Market Share by Region (2017-2028)

Figure 63. China CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Japan CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. South Korea CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. India CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Southeast Asia CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Australia CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. South America CAR T-Cell Immunotherapy Sales Market Share by Type (2017-2028)

Figure 70. South America CAR T-Cell Immunotherapy Sales Market Share by Application (2017-2028)

Figure 71. South America CAR T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 72. Brazil CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Argentina CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Middle East and Africa CAR T-Cell Immunotherapy Sales Market Share by Type (2017-2028)

Figure 75. Middle East and Africa CAR T-Cell Immunotherapy Sales Market Share by Application (2017-2028)

Figure 76. Middle East and Africa CAR T-Cell Immunotherapy Revenue Market Share by Country (2017-2028)

Figure 77. Turkey CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Saudi Arabia CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. UAE CAR T-Cell Immunotherapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Methodology

Figure 81. Research Process and Data Source